Catherine Kelly

Consultant Medical Oncologist Mater Private Hospital and UCD Clinical Professor.   She served as the Head of Breast Medical Oncology at the Mater University Hospital from 2010-2021.  She was elected Chair of the Breast Cancer Group at Cancer Trials Ireland between 2014-2020.  Professor Kelly is a member of multiple international steering committees for breast cancer trials.  She is the Irish PI and co-author for the neoadjuvant trials, NeoTRIP and PenelopeB which have examined immunotherapy and CDK4/6 inhibitors in this setting.  Prof Kelly was the Medical Director of the Mater Clinical Trials Research Unit from 2017 until 2021.   Under her leadership the unit was the highest accruing cancer trials centre in Ireland in 2019.  She has served as international editor for the breast cancer section of the Journal of Clinical Oncology and has written editorials for multiple high impact journals including the JCO, Lancet Oncology and the Journal of the National Cancer Institute.  In 2018 Professor Kelly was awarded the competitive peer reviewed Irish Cancer Society Clinician Leadership Award for her track record in building research teams.  Prof Kelly undertook her specialist medical oncology training in Ireland and the UK.   She completed a Fellowship in Breast Medical Oncology in Toronto where she received the Thomas & Edna Naylor Memorial Award for her research examining tamoxifen drug interactions.   Prior to returning to Ireland in 2010 she was the Susan G. Komen Interdisciplinary Breast Cancer Fellow, at MD Anderson Cancer Center, Houston, Texas, USA.